


Ask a doctor about a prescription for DERCUTANE 30 mg SOFT GEL CAPSULES
Patient Information Leaflet
Dercutane 30 mg Soft Capsules
Isotretinoin
WARNING IF YOU ARE PREGNANT, IT CAN SERIOUSLY HARM YOUR BABY. Women must use effective contraceptives during the entire treatment. Do not use it if you are pregnant or think you may be pregnant. |
Read the entire leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the leaflet:
Isotretinoin belongs to a group of medications called systemic anti-acne preparations that work by suppressing the activity of the sebaceous glands (oil-producing glands) and reducing the size of these glands. Additionally, an anti-inflammatory effect of isotretinoin on the skin has been described.
Dercutane 30 mg is indicated for the treatment of severe forms of acne (e.g., nodular or conglobate acne, or acne with a risk of permanent scarring) that do not respond to conventional treatment with other medications (antibiotics).
Do not take Dercutane 30 mg
Warnings and precautions
Treatment with isotretinoin should be monitored by a doctor who is experienced in the treatment of severe acne and is aware of the risks of treatment with isotretinoin, as well as the danger of birth defects (teratogenicity).
Pregnancy Prevention Plan
Pregnant women must not take Dercutane 30 mg
This medication can seriously harm your baby (the medication is considered "teratogenic", it can cause serious brain, face, ear, eye, heart, and certain gland abnormalities in the baby - thymus and parathyroid). It also increases the risk of spontaneous abortion. This can happen even if Dercutane 30 mg is taken for a short period during pregnancy.
Women who may become pregnant are prescribed Dercutane 30 mg under strict rules. This is due to the risk of serious harm to the baby.
These are the rules:
Women must use effective contraceptives before, during, and after taking Dercutane 30 mg
Women must accept to have pregnancy tests before, during, and after taking Dercutane 30 mg
If you become pregnant while taking Dercutane 30 mg, stop taking the medication immediatelyand consult your doctor. Your doctor may refer you to a specialist for advice.
Additionally, if you become pregnant within one month after stopping Dercutane 30 mg, you should consult your doctor. Your doctor may refer you to a specialist for advice.
Advice for men
The levels of oral retinoids in the semen of men taking Dercutane 30 mg are too low to harm the baby of their partners. However, you should never share your medication with anyone.
Additional precautions
Never give this medication to another person. Please take any unused capsules to your pharmacist at the end of treatment.
Do not donate blood during treatment with this medication, or for one month after stopping Dercutane 30 mg, as a baby could be harmed if a pregnant patient receives your blood.
Consult your doctor before starting to take Dercutane 30 mg:
Mental health problems
You may not notice some changes in your mood and behavior, so it is very important that you tell your friends and family that you are taking this medication. They may notice these changes and help you identify any problems that you need to discuss with your doctor.
Other medications and Dercutane 30 mg
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medications.
Do not take vitamin A supplements or tetracyclines during treatment with Dercutane 30 mg. Taking them together increases the risk of side effects.
Do not use topical keratolytic or exfoliating anti-acne agents, as they may increase local irritation.
Pregnancy, breastfeeding, and fertility
Pregnancy
The use of isotretinoin during pregnancy can cause serious congenital malformations in the fetus and may increase the risk of abortion. Pregnancy is an absolute contraindication for treatment with Dercutane 30 mg. Your doctor must ensure that you are not pregnant before starting treatment, and you must avoid pregnancy during the entire treatment and for one month after finishing treatment. If you become pregnant while taking Dercutane 30 mg, stop taking the medication immediately and consult your doctor. |
For more information on pregnancy and contraception, see the "Pregnancy Prevention Plan" in the "Warnings and Precautions" section.
Breastfeeding
Do not take Dercutane 30 mg during breastfeeding, as isotretinoin may pass into breast milk and harm the newborn. |
Fertility
There is no data to suggest that fertility or offspring of men are affected by taking isotretinoin.
Driving and using machines
Dercutane 30 mg can cause a decrease in night vision in some cases, which can appear suddenly during treatment. Rarely, these disturbances may persist after stopping the medication. If you notice these or other effects on your vision, or if you feel drowsy or dizzy, you should not drive, use machines, or perform any activity that could put you or others at risk.
Dercutane 30 mgcontains soybean oil, sodium, and sorbitol
This medication contains 15.05 mg of sorbitol (E420) per capsule.
This medication contains less than 23 mg of sodium (1 mmol) per capsule; this is essentially "sodium-free".
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Remember to take your medication. Your doctor will indicate the duration of your treatment with Dercutane 30 mg. Do not stop treatment before.
Other presentations are available depending on the dosage recommended by your doctor.
The capsules are taken with food, once or twice a day. You must swallow the capsules whole without chewing or sucking them.
Use in adults, including adolescents and elderly
Usually, treatment starts with a dose of 0.5 mg per kilogram of body weight and day (0.5 mg/kg/day). Your doctor may adjust this dose after a few weeks, depending on your response to treatment. The dose varies between 0.5 and 1.0 mg/kg/day in most cases.
Before starting treatment with Dercutane 30 mg, consult the "Pregnancy Prevention Plan" in the "Warnings and Precautions" section.
Use in patients withseverekidneyfunctionimpairment
Treatment should start with the lowest dose and be increased later.
Use in children
Dercutane 30 mg is not indicated for the treatment of acne that appears before puberty or in children under 12 years of age.
The usual treatment cycle lasts 16 to 24 weeks. Acne may continue to improve up to 8 weeks after finishing treatment. Most patients only need one treatment cycle.
If you think the effect of Dercutane 30 mg is too strong or too weak, tell your doctor or pharmacist.
If you take more Dercutane 30 mg than you should
If you have taken more Dercutane 30 mg than you should, consult your doctor or pharmacist immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist or the nearest hospital or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount taken.
If you forget to take Dercutane 30 mg
Do not take a double dose to make up for forgotten doses.
If you forget a dose, you should take the medication as soon as possible and continue treatment as prescribed. However, when the next administration is near, do not take the forgotten dose and wait for the next administration.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. In general, such effects subside as treatment progresses. Your doctor will help you treat them if they occur.
Severe Adverse Effects
Mental Problems
Rare(may affect up to 1 in 1,000 people):
Very Rare(may affect up to 1 in 10,000 people):
Contact your doctor immediately if you experience signs of any of these mental problems.Your doctor may advise you to stop taking Dercutane 30 mg. This may not be enough to stop the effects: you may need more help, and your doctor can handle it.
It is very important that you inform your doctor if you have suffered from any disease such as depression, suicidal behavior, or psychosis and if you are receiving any medication for the treatment of these diseases.
Other Severe Adverse Effects
Rare(may affect up to 1 in 1,000 people):
Allergic reactions: allergic reaction with chest tightness or difficulty breathing (especially if you are asthmatic) with skin rashes and itching. If you experience an allergic reaction, therapy should be discontinued immediately and you should consult your doctor.
Very Rare(may affect up to 1 in 10,000 people):
Increased intracranial pressure (in the brain): in very rare cases, when isotretinoin is administered together with some antibiotics (tetracyclines), increased intracranial pressure, seizures, and drowsiness have been observed. If you are affected by persistent headache with nausea, vomiting, and blurred vision, this could mean that you are suffering from benign intracranial hypertension. Stop taking isotretinoin as soon as possible and consult your doctor.
Gastrointestinal disorders: pancreatitis (inflammation of the pancreas), gastrointestinal bleeding (blood in the stool), colitis, ileitis (intestinal inflammation), and inflammatory bowel disease. If you experience severe abdominal pain with or without severe diarrhea with blood, and vomiting, stop taking isotretinoin as soon as possible and consult your doctor.
Liver disorders: hepatitis. If your skin or eyes turn yellow and you feel tired, stop taking your medication as soon as possible and consult your doctor.
Kidney disorders: glomerulonephritis (inflammation of the kidneys). You may feel excessively tired, stop urinating, and have swollen and bulging eyelids. If this happens while you are taking your medication, suspend treatment with this medication and consult your doctor.
Frequency Not Known(cannot be estimated from the available data):
Skin disorders: severe skin rash (erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis) that can potentially be life-threatening and require immediate medical attention. They initially appear as circular spots, often with a central blister, usually on arms and hands or legs and feet; more severe rashes can also include blisters on the chest and back. Additionally, symptoms such as eye infection (conjunctivitis) or ulcers in the mouth, throat, or nose may occur. More severe forms of skin rash can lead to generalized peeling of the skin, which can be life-threatening. These types of skin rashes can often be preceded by headache, fever, body aches (symptoms similar to the flu). If you present this type of symptom on the skin, stop taking this medication and contact your doctor immediately.
Non-Severe Adverse Effects
Very Common(may affect more than 1 in 10 people):
Skin and eye disorders:dryness of the skin, lips, and face. You may have throat or skin inflammation, your skin or lips may crack, you may have a rash, some mild itching, and mild peeling. This dryness can be reduced with the regular use of a good moisturizer from the start of treatment.
You may feel your eyes irritated or with conjunctivitis, itching, and redness. You may also notice swollen eyelids. Normally, these adverse effects are reversible once treatment is stopped.
Muscle and bone disorders: lower back pain (lumbalgia), muscle pain, and joint pain. These effects are reversible once you stop treatment. You should try to reduce intense physical activity during treatment with isotretinoin.
Blood and urine test disorders: decrease in hemoglobin in the blood (anemia), decrease or increase in platelets, increase in liver enzymes (transaminases), increase in triglycerides in the blood, and decrease in certain fats (high-density lipoproteins).
Common(may affect up to 1 in 10 people):
Blood and urine test disorders: decrease in white blood cells that can make you more susceptible to infections, increase in cholesterol in the blood, increase in blood sugar, detection of proteins or blood in the urine.
Nervous system disorders: headache.
Respiratory disorders: nasal bleeding, dryness of the nose or inflammation of the nose and throat.
Rare(may affect up to 1 in 1,000 people):
Very Rare(may affect up to 1 in 10,000 people):
Other adverse effects that may occur are the following:
Frequency Not Known(cannot be estimated from the available data)
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medicine out of the sight and reach of children.
Store the blister pack in the outer packaging to protect it from light and moisture.
No special storage conditions are required
Do not use this medicine after the expiration date stated on the box after CAD.:. The expiration date is the last day of the month indicated.
Do not use this medicine if you notice visible signs of deterioration.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point
in the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Return unused capsules to your pharmacist. Store them only if your doctor asks you to.
Composition of Dercutane 30 mg:
Appearance of the Product and Package Contents
Dercutane 30 mg is presented in the form of soft capsules, each capsule has a pink coating containing a viscous opaque liquid of yellow/orange color. Each pack contains 30 or 50 soft capsules. Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
INDUSTRIAL FARMACEUTICA CANTABRIA, S.A.
Barrio Solía 30,
La Concha de Villaescusa
39690 Cantabria (Spain)
Manufacturer:
TOLL MANUFACTURING SERVICES, S.L.
C/ Aragoneses 2,
28108 Alcobendas (Madrid)
Spain
or
INDUSTRIAL FARMACEUTICA CANTABRIA, S.A.
C/ Pirita, 9
28850 Torrejón de Ardoz (Madrid)
Spain
or
EDEFARM, S.L.
Polígono Industrial Enchilagar del Rullo, 117
46191 Villamarchante (Valencia)
Spain
Date of the Last Revision of this Prospectus:February 2024
Detailed and updated information about this product is available by scanning the QR code included in the prospectus using a smartphone. The same information is also available at the following link:http://www.aemps.gob.es

The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for DERCUTANE 30 mg SOFT GEL CAPSULES – subject to medical assessment and local rules.